HIV drug resistance: analysis of viral genotypes and mutation loci in people living with HIV in Chongqing, China (2016-2023).
Drug resistance
Genotype
HIV-1
Thymidine analogue mutation
Journal
AIDS research and therapy
ISSN: 1742-6405
Titre abrégé: AIDS Res Ther
Pays: England
ID NLM: 101237921
Informations de publication
Date de publication:
13 Sep 2024
13 Sep 2024
Historique:
received:
10
01
2024
accepted:
14
08
2024
medline:
14
9
2024
pubmed:
14
9
2024
entrez:
13
9
2024
Statut:
epublish
Résumé
Large-scale HIV genotype drug resistance study has not been conducted in Chongqing. A retrospective study was conducted on people living with HIV(PLWH) who received HIV-1 genotype resistance testing at Chongqing Public Health Medical Center from May 2016 to June 2023. The HIV-1pol gene was amplified through RT-PCR and analyzed in terms of genotypic drug resistance. Of the 3015 PLWH tested for HIV-1 drug resistance, 1405 (46.6%) were resistant to at least one antiviral drug. Among non-nucleoside reverse transcriptase inhibitors (NNRTIs), 43.8% were resistant, compared to 29.5% for nucleoside reverse transcriptase inhibitors (NRTIs) and 3.4% for protease inhibitors (PIs). V179D/E and K103N/S were identified as the common mutation sites in the NNRTIs class of drugs, M184V/I and K65R/N were reported as the most common mutation sites in NRTIs, while thymidine analogue mutation (TAM) group was identified in 373 samples. L10FIV was the most common mutation in PIs. The dominant HIV-1 subtype was CRF07_BC. The high prevalence of HIV-1 drug resistance in Chongqing underscores the imperative for rigorous surveillance of the local HIV epidemic. Furthermore, TAMs are associated with HIV-1 multidrug resistance, and timely detection of drug resistance is helpful to reduce the emergence and spread of such drug-resistant strains.
Sections du résumé
BACKGROUND
BACKGROUND
Large-scale HIV genotype drug resistance study has not been conducted in Chongqing.
METHODS
METHODS
A retrospective study was conducted on people living with HIV(PLWH) who received HIV-1 genotype resistance testing at Chongqing Public Health Medical Center from May 2016 to June 2023. The HIV-1pol gene was amplified through RT-PCR and analyzed in terms of genotypic drug resistance.
RESULTS
RESULTS
Of the 3015 PLWH tested for HIV-1 drug resistance, 1405 (46.6%) were resistant to at least one antiviral drug. Among non-nucleoside reverse transcriptase inhibitors (NNRTIs), 43.8% were resistant, compared to 29.5% for nucleoside reverse transcriptase inhibitors (NRTIs) and 3.4% for protease inhibitors (PIs). V179D/E and K103N/S were identified as the common mutation sites in the NNRTIs class of drugs, M184V/I and K65R/N were reported as the most common mutation sites in NRTIs, while thymidine analogue mutation (TAM) group was identified in 373 samples. L10FIV was the most common mutation in PIs. The dominant HIV-1 subtype was CRF07_BC.
CONCLUSIONS
CONCLUSIONS
The high prevalence of HIV-1 drug resistance in Chongqing underscores the imperative for rigorous surveillance of the local HIV epidemic. Furthermore, TAMs are associated with HIV-1 multidrug resistance, and timely detection of drug resistance is helpful to reduce the emergence and spread of such drug-resistant strains.
Identifiants
pubmed: 39272106
doi: 10.1186/s12981-024-00646-z
pii: 10.1186/s12981-024-00646-z
doi:
Substances chimiques
Anti-HIV Agents
0
Reverse Transcriptase Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
62Subventions
Organisme : Technology Innovation and Application Development Project of Chongqing Shapingba District
ID : 202316
Organisme : Technology Innovation and Application Development Project of Chongqing Shapingba District
ID : 202316
Organisme : Joint Medical Research Projects of Chongqing Municipal Health Committee and Chongqing Municipal Science and Technology Bureau
ID : 2020FYYX112
Organisme : Joint Medical Research Projects of Chongqing Municipal Health Committee and Chongqing Municipal Science and Technology Bureau
ID : 2020FYYX112
Organisme : Joint Medical Research Projects of Chongqing Municipal Health Committee and Chongqing Municipal Science and Technology Bureau
ID : 2020FYYX112
Organisme : Joint Medical Research Projects of Chongqing Municipal Health Committee and Chongqing Municipal Science and Technology Bureau
ID : 2020FYYX112
Informations de copyright
© 2024. The Author(s).
Références
The Joint United Nations Programme on HIV/AIDS, Global HIV. & AIDS statistics—2020 fact sheet [EB/OL]. (2021-01-18). https://www.unaids.org/en/resources/fact-sheet
World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach[M]. 2nd ed. Geneva; 2016.
Gandhi RT, Bedimo R, Hoy JF, Landovitz RJ, Smith DM, Eaton EF, Lehmann C, Springer SA, Sax PE, Thompson MA, Benson CA, Buchbinder SP, Del Rio C, Eron JJ Jr, Günthard HF, Molina JM, Jacobsen DM, Saag MS. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2022 recommendations of the international antiviral society-USA panel. JAMA. 2023;329(1):63–84.
doi: 10.1001/jama.2022.22246
pubmed: 36454551
Chen M, Zhu Q, Xing H, Chen H, Jin X, Dong L, Dai J, Yang M, Yang C, Jia M, Ma Y. The characteristics of pretreatment HIV-1 drug resistance in western Yunnan, China. Epidemiol Infect. 2020;148:e102.
doi: 10.1017/S095026882000093X
pubmed: 32381145
pmcid: 7315466
Wheeler WH, Ziebell RA, Zabina H, Pieniazek D, Prejean J, Bodnar UR, Mahle KC, Heneine W, Johnson JA, Hall HI. Variant atypical, and resistant HIV surveillance group. prevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, U.S.-2006. AIDS. 2010;24(8):1203–12.
doi: 10.1097/QAD.0b013e3283388742
pubmed: 20395786
Renni DENG, Jing HE, Fengfeng LIU, Jungang LI, Qinghua LI, Jing WANG. Surveillance of HIV-1 transmitted drug resistance mutation among newly diagnosed HIV-1 individuals in Chongqing. J Third Military Med Univ. 2018;40(03):270–4. Chinese.
Yanqiu LU, Jing WANG, Yaokai CHEN, Jungang LI. A retrospective study on drug resistance in HIV-1 infected patients failing first-line antiretroviral therapy in Chongqing. Chin J Infect Chemother. 2021;21(4):5 (Chinese).
Liu M, He XQ, Deng RN, Tang SQ, et al. Pretreatment drug resistance in people living with HIV: a large retrospective cohort study in Chongqing, China. HIV Med. 2022;23(Suppl 1):95–105.
doi: 10.1111/hiv.13253
pubmed: 35293098
pmcid: 9311700
Liang S, Liu Z, Wang S, et al. The genotype distribution, infection stage and drug resistance mutation profile of human immunodeficiency virus- 1 among the infected blood donors from five Chinese blood centers, 2014– 2017. PLoS ONE. 2020;15:e0243650.
doi: 10.1371/journal.pone.0243650
pubmed: 33347449
pmcid: 7752150
He X, Xing H, Ruan Y, et al. Group for HIV molecular epidemiologic survey. A comprehensive mapping of HIV-1 genotypes in various risk groups and regions across China based on a nationwide molecular epidemiologic survey. PLoS ONE. 2012;7(10):e47289.
doi: 10.1371/journal.pone.0047289
pubmed: 23056619
pmcid: 3466245
Feng Y, Takebe Y, Wei H, et al. Geographic origin and evolutionary history of China’s two predominant HIV-1 circulating recombinant forms, CRF07_BC and CRF08_BC. Sci Rep. 2016;6:19279.
doi: 10.1038/srep19279
pubmed: 26763952
pmcid: 4725877
Kantor R, Katzenstein D. Drug resistance in non-subtype B HIV-1. J Clin Virol. 2004;29(3):152–9.
doi: 10.1016/S1386-6532(03)00115-X
pubmed: 14962783
Chaplin B, Akanmu AS, Inzaule SC, Samuels JO, Okonkwo P, Ilesanmi O, et al. Association between HIV-1 subtype and drug resistance in Nigerian infants. J Antimicrob Chemother. 2019;74(1):172–6.
doi: 10.1093/jac/dky380
pubmed: 30260417
Lessells RJ, Katzenstein DK, de Oliveira T. Are subtype differences important in HIV drug resistance? Curr Opin Virol. 2012;2(5):636–43.
doi: 10.1016/j.coviro.2012.08.006
pubmed: 23006584
pmcid: 3951383
Chen M, Zhu Q, Xing H, et al. The characteristics of pretreatment HIV- 1 drug resistance in western Yunnan, China. Epidemiol Infect. 2020;148:e102.
doi: 10.1017/S095026882000093X
pubmed: 32381145
pmcid: 7315466
Geretti AM, editor. Antiretroviral resistance in clinical practice. London: Mediscript; 2006.
McCluskey SM, Siedner MJ, Marconi VC. Management of virologic failure and HIV drug resistance. Infect Dis Clin North Am. 2019;33(3):707–42.
doi: 10.1016/j.idc.2019.05.004
pubmed: 31255384
pmcid: 6688946
Bertagnolio S, Jordan MR, Doherty M. HIV drug resistance. N Engl J Med. 2018;378(9):874.
pubmed: 29504388
Marcelin AG, Charpentier C, Wirden M, Landman R, Valantin MA, Simon A, et al. Resistance profiles of emtricitabine and lamivudine in tenofovir-containing regimens. J Antimicrob Chemother. 2012;67(6):1475–8.
doi: 10.1093/jac/dks047
pubmed: 22371439
Margot N, Ram R, Abram M, Haubrich R, Callebaut C. Antiviral activity of tenofovir alafenamide against HIV-1 with thymidine analog-associated mutations and M184V. Antimicrob Agents Chemother. 2020;64(4):e02557–19.
doi: 10.1128/AAC.02557-19
pubmed: 31988104
pmcid: 7179327
Gregson J, Kaleebu P, Marconi VC, van Vuuren C, Ndembi N, Hamers RL, et al. Occult HIV-1 drug resistance to thymidine analogues following failure of first-line tenofovir combined with a cytosine analogue and nevirapine or efavirenz in sub Saharan Africa: a retrospective multi-centre cohort study. Lancet Infect Dis. 2017;17(3):296–304.
doi: 10.1016/S1473-3099(16)30469-8
pubmed: 27914856
Farrokhi M, Gholami M, Mohraz M, McFarland W, Baesi K, Abbasian L. HIV drug resistance among naïve HIV-infected patients in Iran. J Res Med Sci. 2019;24:31.
doi: 10.4103/jrms.JRMS_689_18
pubmed: 31143232
pmcid: 6521612
De Waal R, Lessells R, Hauser A, Kouyos R, Davies MA, Egger M, et al. HIV drug resistance in sub-saharan Africa: public health questions and the potential role of real-world data and mathematical modelling. J Virus Erad. 2018;4(Suppl 2):55–8.
doi: 10.1016/S2055-6640(20)30347-2
pubmed: 30515315
pmcid: 6248850